Hematologic Malignancy
Mature B-Cell Neoplasm
CI-CAN-00003258Explore in graph →
HematologicNon-malignant1,787 active trials44 approved drugs119 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003258Explore in graph →
Clinical trials
6,663 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06977711 | Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL) | recruiting | Phase 1 | 10 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07409246 | A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM) | recruiting | Phase 1 | 127 | AbbVieINDUSTRY | 4 |
| Sep 29, 2026 |
| clinicaltrials |
| NCT03223610 | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma | recruiting | Phase 1 / Phase 2 | 155 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04973605 | A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 246 | BeOne MedicinesINDUSTRY | 13 | Sep 28, 2026 | clinicaltrials |
| NCT05006716 | A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies(CaDAnCe-101) | recruiting | Phase 1 / Phase 2 | 645 | BeOne MedicinesINDUSTRY | 16 | Sep 28, 2026 | clinicaltrials |
| NCT06697184 | A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. | recruiting | Phase 1 / Phase 2 | 258 | BeOne MedicinesINDUSTRY | 6 | Sep 28, 2026 | clinicaltrials |
| NCT07660939 | GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders | recruiting | Phase 1 | 50 | Peking University First HospitalOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03460977 | A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma | recruiting | Phase 1 | 453 | PfizerINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT06768489 | A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma | recruiting | Phase 1 | 276 | Janssen Research & Development, LLCINDUSTRY | 5 | Sep 25, 2026 | clinicaltrials |
| NCT07336472 | A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 360 | Fortvita Biologics (USA)Inc.INDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07519772 | A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)(WaveSpan-008) | recruiting | Phase 1 / Phase 2 | 280 | Merck Sharp & Dohme LLCINDUSTRY | 14 | Sep 25, 2026 | clinicaltrials |
| NCT07116616 | A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 190 | ModernaTX, Inc.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06465316 | Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07101328 | A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )(BAF_FRontier-1) | recruiting | Phase 1 | 215 | Eli Lilly and CompanyINDUSTRY | 12 | Sep 22, 2026 | clinicaltrials |
| NCT07226843 | A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers | recruiting | Phase 1 | 460 | Eli Lilly and CompanyINDUSTRY | 8 | Sep 22, 2026 | clinicaltrials |
| NCT03909412 | Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma(CarMob) | recruiting | Phase 1 | 18 | Hackensack Meridian HealthOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06029309 | Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma(ZANU-TAFA) | recruiting | Phase 1 / Phase 2 | 27 | Alvaro Alencar, MDOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07802717 | A Phase 1 Dose-escalation and Expansion Study of In Vivo BCMA-CAR T Cell Therapy (VV169) in Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 40 | Vyriad, Inc.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07210047 | Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients | recruiting | Phase 1 / Phase 2 | 21 | HuniLife Biotechnology, Inc.INDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07422610 | Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment | recruiting | Phase 1 | 24 | Novartis PharmaceuticalsINDUSTRY | 4 | Sep 18, 2026 | clinicaltrials |
| NCT04879043 | Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 78 | Heidelberg Pharma AGINDUSTRY | 5 | Sep 17, 2026 | clinicaltrials |
| NCT04910568 | A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma(CAMMA 1) | recruiting | Phase 1 | 186 | Genentech, Inc.INDUSTRY | 13 | Sep 17, 2026 | clinicaltrials |
| NCT06395103 | Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | recruiting | Phase 1 / Phase 2 | 90 | Merck Sharp & Dohme LLCINDUSTRY | 23 | Sep 17, 2026 | clinicaltrials |
| NCT07760454 | A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 68 | UCARsgen Biotech LimitedOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04815356 | Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant | recruiting | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05892393 | Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma | recruiting | Phase 1 | 20 | Robert Flavell, MD, PhDOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06345027 | Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)(CASEY) | recruiting | Phase 1 | 78 | Baylor College of MedicineOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06735664 | Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation | recruiting | Phase 1 | 23 | City of Hope Medical CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07181941 | Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07343934 | huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma | recruiting | Phase 1 | 6 | University of PennsylvaniaOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07620275 | Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA | recruiting | Phase 1 | 9 | Chinese PLA General HospitalOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06953960 | A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) | recruiting | Phase 1 / Phase 2 | 325 | AbbVieINDUSTRY | 12 | Sep 14, 2026 | clinicaltrials |
| NCT07558915 | A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | recruiting | Phase 1 | 160 | Genentech, Inc.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06049290 | A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 342 | Nanjing Leads Biolabs Co.,LtdINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06830031 | Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma(C402) | recruiting | Phase 1 | 18 | Shanghai Exuma Biotechnology Ltd.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07455851 | A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 150 | Regeneron PharmaceuticalsINDUSTRY | 2 | Sep 11, 2026 | clinicaltrials |
| NCT05272384 | Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma | recruiting | Phase 1 | 32 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07570017 | A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma | recruiting | Phase 1 | 42 | Guangzhou Lupeng Pharmaceutical Company LTD.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07225439 | Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | recruiting | Phase 1 | 15 | Paolo Caimi, MDOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05091424 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia | recruiting | Phase 1 | 332 | Hoffmann-La RocheINDUSTRY | 10 | Sep 8, 2026 | clinicaltrials |
| NCT06564038 | A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies(Soundtrack-E) | recruiting | Phase 1 / Phase 2 | 408 | AstraZenecaINDUSTRY | 13 | Sep 8, 2026 | clinicaltrials |
| NCT05533775 | A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma(iMATRIX GLO) | recruiting | Phase 1 / Phase 2 | 65 | Hoffmann-La RocheINDUSTRY | 13 | Sep 3, 2026 | clinicaltrials |
| NCT05583617 | A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma(PLYCOM) | recruiting | Phase 1 / Phase 2 | 200 | Hoffmann-La RocheINDUSTRY | 6 | Sep 3, 2026 | clinicaltrials |
| NCT05927571 | A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) | recruiting | Phase 1 | 120 | Genentech, Inc.INDUSTRY | 3 | Sep 3, 2026 | clinicaltrials |
| NCT07332507 | Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07479979 | Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 62 | Natalie CallanderOTHER | 1 | Aug 31, 2026 | clinicaltrials |
Data updated 17 hours agoSource updated Sep 29, 2026source: clinicaltrials